MINDCURE announces new formulations for its proprietary synthetic ibogaine, supported by a new patent application.
Revitalist and PharmaTher Announce Collaboration to Develop and Advance Novel and Standardized Ketamine Treatment Protocols for Mental Health Disorders and Chronic Pain Syndromes
Revitalist and Pharmather to collaborate on novel and standardized treatment protocols for for ketamine-based psychotherapy.
Red Light Holland Reports Fiscal Third Quarter Results
Red Light Holland reports quarterly revenue growth of 28% and gross profit growth of 48% for Q3 of fiscal 2022. Strong cash position of CAD$27.3 million.
Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study
Mydecine prepares to submit its IND and application for Breakthrough Therapy Status for smoking cessation after successful meeting with FDA.
Novamind Reports Fiscal Q2 2022 Financial Results and Operating Highlights
Novamind reports 32% q-o-q revenue growth, up to CAD $2.45 million in its latest quarter. Cash balance of ~CAD$8 million including post-period financing.
Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules
Enveric Biosciences announces the filing of its 10th patent application for its tryptamine-based molecules.
Gold price up as high anxiety grips marketplace
Gold and silver prices are sharply higher in early U.S. trading Monday, on safe-haven demand as the Russia-Ukraine geopolitical situation is deteriorating.
Revitalist Receives Approval from Biomedical Research Alliance of New York Permitting the Company to Perform Human Subjects Clinical Trials
Revitalist obtains regulatory approval for its clinics to host human clinical trials for psychedelics-based therapies.
Why Microdosing Cannot Replace Psychedelic Medicine
Psychedelic medicine is proving it can provide spectacular treatment results for many mental health disorders. Microdosing may also be an important therapy tool. But there's a catch.
COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights
COMPASS Pathways reported its financial results for the fourth quarter and full year 2021 and gave an update on recent progress across its business.
Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022
Pasiethea Therapeutics plans to offer three new clinics offering both ketamine-based and "repeated transcranial magnetic stmulation" treatments (rTMS).
Gold price moves past $1,900 as tensions mount in Ukraine
Gold prices rose above the key $1,900 an ounce level, its highest level since the end of May 2021.
